Lynch Daniel
SEC-identified person · CIK 1177082 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Springworks Therapeutics, Inc. [SWTX | Director | filed 2019 - 2025 |
| 2Seventy bio, Inc. TSVT | Director | filed 2021 - 2023 |
| Bluebird bio, Inc. BLUE | Director | filed 2013 - 2021 |
| Xilio Therapeutics, Inc. XLO | Director | filed 2021 - 2021 |
| Translate Bio, Inc. TBIO | Director | filed 2018 - 2021 |
| Omega Alpha Spac OMEG | Director | filed 2021 - 2021 |
| Blueprint Medicines Corp BPMC | Director | filed 2015 - 2020 |
| Surface Oncology, Inc. SURF | Director | filed 2018 - 2020 |
| Sesen Bio, Inc. SESN | Director | filed 2014 - 2019 |
| Dnib Unwind, INC. BIND | Director · Chairman | filed 2013 - 2016 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.